Perrigo Company plc Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31)
Perrigo Company plc (PRGO) reported Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) of $5.40 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Equity
us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1 · last filed 2018-03-01
- Perrigo Company plc cumulative effect on retained earnings, net of tax (deprecated 2020-01-31) for fiscal 2017 was $5.40M.
| Period end | Cumulative Effect on Retained Earnings, Net of Tax (Deprecated 2020-01-31) 12 month |
|---|---|
| 2017-12-31 | $5.40M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |